CIRM Funded Clinical Trials
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome
Disease Area:
Developmental Disorders, Genetic Disorder, Other
Trial Sponsor:
Mahzi Therapeutics
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A